Navigation Links
Beaumont Patients 1st to get Next Generation of Radiation Treatment
Date:9/20/2007

ROYAL OAK, Mich., Sept. 20 /PRNewswire/ -- Cancer patients at Beaumont Hospitals are the first in the world to be treated with the next generation of radiation therapy that is painless, faster, more accurate and precise than other treatments.

Beaumont doctors and physicists invented and patented the new technology, Omnibeam(R). The $3.3-million machine is manufactured in England by Elekta, which is headquartered in Stockholm. The first patient was treated on Sept. 10.

The painless treatment takes about 20 minutes and requires no implants or invasive procedures to prepare for therapy. It can be used to treat cancer of the breast; prostate; lungs; and head and neck, as well as other cancers. It is specially designed for the treatment of tumors deep within the body.

Omnibeam(R), a robotic technology, uses highly accurate, real-time CT imaging that automatically adjusts the radiation field during treatment to account for a patient's external movements - and the natural repositioning of internal organs - from day to day or even moment to moment. Omnibeam(R) also uses robotic technology to adjust the treatment table on which a patient lies to provide pinpoint accuracy of treatment. Adjusting the radiation field and treatment table means the radiation treatment is precisely targeted to kill cancer cells, destroying them without harming surrounding healthy tissue or organs. The patient has better cancer control and fewer undesirable side effects as a result.

"Omnibeam(R) is a dramatic new clinical advance in radiation therapy for cancer. The combination of improved imaging coupled with robotic technology is vastly better than other radiation machines for cancer therapy," says Alvaro Martinez, M.D., corporate chairman of Radiation Oncology for Beaumont Hospitals. "It uses advanced imaging technology, is faster, can treat from very small to very large, irregularly shaped tumors and does not require placement of metal implants as with other therapies. Its robotic component tracks a patient's movements on a real-time basis and corrects the treatment accordingly."

Dr. Martinez was inspired to "marry" CT imaging with a medical linear accelerator when, while attending a medical symposium in Dearborn, he stumbled upon a meeting of Ford Motor Company automotive engineers who were using imaging to detect defects in engine blocks. It took more than five years for him and his team to adapt and perfect the auto technology for cancer radiation treatment.

Contact Beaumont's Radiation Oncology department at 248-551-8819 for more information about Omnibeam(R).

When the diagnosis is cancer and radiation treatment is needed, the hospitals' Radiation Oncology department offers the most advanced therapies, including intensity modulated radiation therapy and image-guided radiation treatment, whether external-beam or brachytherapy (internal radiation). The department is a world-renowned pioneer in advancing radiation therapy that is more precise, paving the way for better cancer control and fewer undesirable side effects.


'/>"/>
SOURCE William Beaumont Hospitals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ┬« (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center ... be awarded for the fall semester to a deserving student. Get your applications ... 2017 scholarship was awarded to Mariana Castillo who is a nursing student at Prairie ...
(Date:7/24/2017)... Los Angeles, California (PRWEB) , ... July 24, ... ... office building fire in Oakland, California effectively destroyed the construction site and threatened ... to a July 7th article on NBCLosAngeles.com. Los Angeles Area ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , ... announced it has partnered with WALLIX to expand its solution to help ... , There are a number of ways to address the authentication requirements within ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global ... the issuance of United States Patent Number 9,695,398 (the '398 patent) and South ... The '398 and '324 patents cover methods and systems for optimizing fat grafts ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
Breaking Medicine News(10 mins):